Drug intelligence / Profile preview

bupropion + duloxetine

Development stage
Preclinical
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

Bupropion + duloxetine is a combination of two antidepressant medications, each with distinct mechanisms of action. Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI), while duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI). This combination has been studied for use in treatment-resistant major depressive disorder, where monotherapy with either agent was insufficient. The rationale for combining these drugs lies in their complementary pharmacological profiles, potentially offering broader neurotransmitter modulation and improved efficacy in certain patients. However, the combination carries an increased risk of adverse effects and drug interactions, including the potential for serotonin syndrome and elevated blood pressure[2][1][3]. Use should be closely monitored by healthcare professionals.

02

Targets

SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on bupropion + duloxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupropion + duloxetine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call